Cas no 863127-77-9 (Dasatinib monohydrate)
Dasatinib monohydrate Chemical and Physical Properties
Names and Identifiers
-
- Dasatinib monohydrate
- N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate
- Dasatinib
- Dasatinib (monohydrate)
- N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide,hydrate
- Dasatinib hydrate (JAN)
- dasatinib.H2O
- N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide monohydrate
- N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrim
- SPRYCEL (TN)
- UNII-RBZ1571X5H
- 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, monohydrate (9CI)
- BMS 35482503
- Dasatinib hydrate
- MFCD08704581
- DTXSID50235486
- 863127-77-9
- CHEBI:70839
- DASATINIB [ORANGE BOOK]
- HMS3264K15
- NSC 759877
- N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide hydrate
- N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;hydrate
- BCP09727
- DASATINIB MONOHYDRATE [WHO-DD]
- 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, monohydrate
- Q27139135
- SB17285
- CS-0019773
- 863127-77-9 (hydrate)
- GS-4248
- s7782
- D06414
- EN300-7359810
- BD164354
- DASATINIB [JAN]
- N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide--water (1/1)
- 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, hydrate (1:1)
- HMS3886B19
- N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide hydrate
- CCG-269744
- RBZ1571X5H
- 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, hydrate (1:1); 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, monohydrate (9CI); BMS 35482503; Dasatinib hydrate; Dasatinib monohydrate
- AKOS015855318
- Dasatinib monohydrate?
- BMS-354825 Monohydrate
- Dasatinib [USAN]
- HY-10181B
- N-(2-chloro-6-methylphenyl)-2-((6-(4-(2- hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide hydrate
- BMS 354825-03
- N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
- Dasatinib (USAN)
- DASATINIB [VANDF]
- N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide hydrate
- N-(2-chloranyl-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide hydrate
- BMS-354825-03
- N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]thiazole-5-carboxamide hydrate
- XHXFZZNHDVTMLI-UHFFFAOYSA-N
- SCHEMBL290515
- A841605
- Dasatinib [USAN:INN:BAN:JAN]
- N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide hydrate
- DASATINIB HYDRATE [JAN]
- DASATINIB [EMA EPAR]
- N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide monohydrate.
-
- MDL： MFCD08704581
- Inchi： 1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2
- InChI Key： XHXFZZNHDVTMLI-UHFFFAOYSA-N
- SMILES： O=C(C1=CN=C(NC2C=C(N3CCN(CCO)CC3)N=C(C)N=2)S1)NC1C(C)=CC=CC=1Cl.O
Computed Properties
- Exact Mass: 505.16600
- Monoisotopic Mass: 505.166286
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 10
- Heavy Atom Count: 34
- Rotatable Bond Count: 8
- Complexity: 642
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 11
- XLogP3: nothing
- Topological Polar Surface Area: 136
Experimental Properties
- Color/Form: Powder
- Density: 1.408
- PSA: 143.98000
- LogP: 3.39810
Dasatinib monohydrate Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H332-H335
- Warning Statement： P261-P280-P305+P351+P338
- Hazardous Material transportation number：UN 3263 8/PG 2
- WGK Germany：3
- Safety Instruction： S26; S27; S28
- RTECS：QD8530000
-
Hazardous Material Identification：
- Storage Condition：Keep in dark place,Sealed in dry,Store in freezer, under -20°C(BD213871)
- Safety Term：4.3
- Packing Group：II
- Risk Phrases：R34; R36/37/38
Dasatinib monohydrate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| S e l l e c k ZHONG GUO | S7782-50mg |
Dasatinib Monohydrate |
863127-77-9 | 99.62% | 50mg |
￥811.64 | 2023-09-15 | |
| S e l l e c k ZHONG GUO | S7782-200mg |
Dasatinib Monohydrate |
863127-77-9 | 99.62% | 200mg |
￥1610.04 | 2023-09-15 | |
| TRC | D193638-50mg |
Dasatinib Monohydrate |
863127-77-9 | 50mg |
$ 57.00 | 2023-09-08 | ||
| TRC | D193638-250mg |
Dasatinib Monohydrate |
863127-77-9 | 250mg |
$ 64.00 | 2023-09-08 | ||
| TRC | D193638-500mg |
Dasatinib Monohydrate |
863127-77-9 | 500mg |
$97.00 | 2023-05-18 | ||
| TRC | D193638-1g |
Dasatinib Monohydrate |
863127-77-9 | 1g |
$ 159.00 | 2023-09-08 | ||
| ChemScence | CS-0019773-1g |
Dasatinib (monohydrate) |
863127-77-9 | 1g |
$105.0 | 2021-09-02 | ||
| ChemScence | CS-0019773-5g |
Dasatinib (monohydrate) |
863127-77-9 | 5g |
$367.0 | 2021-09-02 | ||
| ChemScence | CS-0019773-10g |
Dasatinib (monohydrate) |
863127-77-9 | 10g |
$645.0 | 2021-09-02 | ||
| BAI LING WEI Technology Co., Ltd. | 1020809-50MG |
Dasatinib monohydrate, 99%, a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM |
863127-77-9 | 99% | 50MG |
￥ 31 | 2022-04-26 |
Dasatinib monohydrate Related Literature
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
-
Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
-
Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
-
J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
-
Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
Additional information on Dasatinib monohydrate
Dasatinib Monohydrate (CAS No. 863127-77-9): A Comprehensive Overview in Modern Oncology
Dasatinib monohydrate, identified by its Chemical Abstracts Service (CAS) number 863127-77-9, is a significant compound in the realm of targeted cancer therapy. As a potent tyrosine kinase inhibitor, it has garnered substantial attention for its role in treating various hematological malignancies, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This introduction delves into the pharmacological properties, clinical applications, and recent advancements associated with this molecule.
The molecular structure of Dasatinib monohydrate is characterized by its ability to selectively inhibit multiple protein kinases involved in cancer cell proliferation and survival. Its chemical formula, C22H27N5O42O, underscores its complex yet well-defined composition. This intricate architecture allows it to bind tightly to the ATP-binding sites of target kinases, thereby disrupting critical signaling pathways such as the BCR-ABL and SRC family kinases. Such selectivity has made it a cornerstone in the management of Philadelphia chromosome-positive (Ph+) leukemias.
In clinical practice, Dasatinib monohydrate has been extensively studied for its efficacy in both newly diagnosed and resistant Ph+ CML patients. The drug's ability to overcome resistance mutations that develop during imatinib therapy has been particularly noteworthy. Recent clinical trials have demonstrated that patients treated with Dasatinib monohydrate exhibit high rates of hematologic and cytogenetic response, even in cases where prior therapies have failed. This resilience against resistance underscores its therapeutic value and highlights the importance of continuous research into optimizing its use.
The pharmacokinetic profile of Dasatinib monohydrate is another critical aspect that contributes to its clinical success. Following oral administration, the compound exhibits rapid absorption with a median time to peak concentration typically observed within 1 to 3 hours. Its bioavailability is relatively high, allowing for once-daily dosing regimens that enhance patient compliance. Moreover, the drug's prolonged half-life ensures sustained therapeutic levels, minimizing the need for frequent dosing adjustments.
Recent research has expanded the therapeutic applications of Dasatinib monohydrate beyond Ph+ leukemias. Studies have explored its potential in other malignancies characterized by aberrant tyrosine kinase activity, such as certain solid tumors and myeloproliferative neoplasms. Preclinical data suggest that Dasatinib monohydrate may exert anti-tumor effects by inhibiting downstream signaling cascades involved in cell growth and angiogenesis. While further clinical validation is needed, these findings open new avenues for investigating its role in broader oncological settings.
The development of formulations for improved delivery and bioavailability has also been a focus area for researchers working with Dasatinib monohydrate. Novel formulations, including extended-release tablets and liquid suspensions, have been designed to enhance patient convenience and reduce dosing frequency. These advancements not only improve treatment adherence but also expand access to patients who may have difficulty swallowing traditional tablets.
Safety considerations remain a paramount focus when evaluating the use of Dasatinib monohydrate. Common adverse effects include hematologic abnormalities such as thrombocytopenia and anemia, as well as non-hematologic events like nausea and fatigue. However, with appropriate monitoring and management strategies, most side effects can be effectively mitigated. Ongoing research aims to identify biomarkers that can predict individual responses to therapy, thereby enabling personalized treatment approaches.
The integration of genomics and proteomics into the treatment paradigm has further enhanced the utility of Dasatinib monohydrate. By analyzing genetic mutations and protein expression patterns in patient samples, clinicians can tailor therapy to optimize outcomes. This personalized medicine approach aligns with broader trends in oncology toward precision-based treatments that leverage molecular insights for better patient care.
In conclusion, Dasatinib monohydrate (CAS No. 863127-77-9) represents a significant advancement in targeted cancer therapy. Its potent anti-leukemic activity, resistance management capabilities, and evolving applications make it a cornerstone in modern oncology. As research continues to uncover new therapeutic possibilities and refine delivery methods, this compound is poised to remain at the forefront of cancer treatment strategies for years to come.
863127-77-9 (Dasatinib monohydrate) Related Products
- 936845-86-2(tert-Butyl 4-(2-methyl-6-((5-vinylthiazol-2-yl)amino)pyrimidin-4-yl)piperazine-1-carboxylate)
- 21673-86-9(2-amino-N-(2,6-diethylphenyl)-4-methyl-1,3-thiazole-5-carboxamide)
- 303987-39-5(2-(4-phenylpiperazin-1-yl)-1,3-thiazole-5-carbaldehyde)
- 936845-85-1(tert-Butyl 4-(6-((5-formylthiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazine-1-carboxylate)
- 142287-36-3(Pyrimido[4,5-d]pyrimidin-4(1H)-one,2,3-dihydro-7-methyl-1-phenyl-3-[3-[4-(2-thiazolyl)-1-piperazinyl]propyl]-2-thioxo-)
- 21697-42-7(2-amino-4-methyl-N-(2,4,6-trimethylphenyl)-1,3-thiazole-5-carboxamide)
- 1159977-25-9(2’-Deschloro-2’-hydroxy Dasatinib)
- 13807-15-3(4-amino-2-anilino-thiazole-5-carboxamide)
- 175856-45-8(3H-Pyrazolo[3,4-d]thiazol-3-one,1,2-dihydro-5-[(4-methylphenyl)amino]-1-phenyl-)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
